Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Hoatzin who wrote (9337)	3/10/2003 6:47:05 PM
From: N. Dixon	Read Replies (1) \| Respond to of 10293

Not that old line again. Tell your boss we've heard it all before. In yesterday’s press release, Mr. Manuel Asensio claims that Research Frontiers is engaged in the sale of unregistered stock in connection with an investment by London-based money management firm, Ailouros Ltd. Mr. Asensio’s statement is clearly wrong since this transaction and the sale of stock thereunder has been registered with the U.S. Securities and Exchange Commission as a public offering of securities. Mr. Asensio also claims to find no record of Ailouros Ltd. being registered with the U.K.’s Financial Services Authority. As with hedge funds and private institutional investors here in the United States, such registration is not required of Ailouros in the U.K., and it is in compliance with all applicable laws. Another example of Mr. Asensio’s attempt to mislead the public is his citation of stock prices for some of the various companies that Ailouros Ltd. had invested in. While citing current stock prices is irrelevant in itself, Mr. Asensio’s deception goes much deeper. For instance, he cites Roberts Pharmaceutical Corp. as one investment of Ailouros which Mr. Asensio claims currently trades at $0.006 per share. When Mr. Asensio pulls up a quote on RPCX which was the former trading symbol for Roberts Pharmaceutical Corp., he would clearly see that this is a quote for a different company called ReSourcePhoenix.Com. The last trade for Roberts Pharmaceutical Corp. was $29.625 on December 22, 1999 which was the day prior to the publicly announced acquisition of Roberts Pharmaceuticals for $1 billion by Shire Pharmaceuticals Group plc. Given that it was a simple matter for Research Frontiers to discover this information within minutes using nothing more than the Internet, this shows that Mr. Asensio’s "research" is at best, irrelevant, shoddy and self-serving. When considered in light of Mr. Asensio’s record of mixing up company names to mislead the public and defame Research Frontiers licensee ThermoView Industries, it is evident that this was an intentional attempt by Mr. Asensio to mislead the investing public about yet another company that Research Frontiers does business with.